M
M. Deinert
Publications - 11
Citations - 580
M. Deinert is an academic researcher. The author has contributed to research in topics: Pimobendan & Heart failure. The author has an hindex of 6, co-authored 11 publications receiving 459 citations.
Papers
More filters
Journal ArticleDOI
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Jens Häggström,Adrian Boswood,Michael R. O'Grady,Olaf Jöns,Sarah Smith,Simon Swift,M. Borgarelli,B. Gavaghan,Jan-Gerd Kresken,M. Patteson,B. Åblad,Claudio Bussadori,Tony M. Glaus,A. Kovacevic,M. Rapp,Roberto A. Santilli,Anna Tidholm,A. Eriksson,M.C. Belanger,M. Deinert,C.J.L. Little,Clarence Kvart,Anne French,M. Ronn-Landbo,Gerhard Wess,A.V. Eggertsdottir,M.L. O'Sullivan,Matthias Schneider,Christophe W. Lombard,Joanna Dukes-McEwan,Ruth Willis,A. Louvet,Rocky DiFruscia +32 more
TL;DR: Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazeprilplus conventional therapy.
Journal ArticleDOI
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial
Adrian Boswood,Jens Häggström,Sonya G. Gordon,Gerhard Wess,Rebecca L. Stepien,Mark A. Oyama,Bruce W. Keene,John D. Bonagura,Kristin A. MacDonald,M. Patteson,Sarah Smith,Philip R. Fox,Karen Sanderson,Richard Woolley,Viktor Szatmári,Pierre Menaut,Whitney M. Church,M. L. O'Sullivan,J-P Jaudon,J-G Kresken,John E. Rush,Kirstie A. Barrett,Steven L. Rosenthal,Ashley B. Saunders,Ingrid Ljungvall,M. Deinert,Eric Bomassi,Amara H. Estrada,M. J. Fernández del Palacio,N.S. Moïse,Jonathan A. Abbott,Yoko Fujii,Alan W. Spier,Michael W. Luethy,Roberto A. Santilli,Masami Uechi,Anna Tidholm,P. Watson +37 more
TL;DR: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated.
Journal ArticleDOI
Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving Pimobendan or Benazepril: the QUEST study
Jens Häggström,Adrian Boswood,Michael R. O'Grady,Olaf Jöns,Sarah Smith,Simon Swift,M. Borgarelli,B. Gavaghan,Jan-Gerd Kresken,M. Patteson,B. Åblad,Claudio Bussadori,Toni M Glaus,A. Kovacevic,M. Rapp,Roberto A. Santilli,Anna Tidholm,A. Eriksson,M.C. Belanger,M. Deinert,C.J.L. Little,Clarence Kvart,Anne French,M. Ronn-Landbo,Gerhard Wess,A.V. Eggertsdottir,M. Lynne O'Sullivan,Matthias Schneider,Christophe W. Lombard,Joanna Dukes-McEwan,Ruth Willis,A. Louvet,Rocky DiFruscia +32 more
TL;DR: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment.
Journal ArticleDOI
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo : The EPIC Study
Adrian Boswood,Sonya G. Gordon,Jens Häggström,Gerhard Wess,Rebecca L. Stepien,Mark A. Oyama,Bruce W. Keene,John D. Bonagura,Kristin A. MacDonald,M. Patteson,Sarah Smith,Philip R. Fox,Karen Sanderson,Richard Woolley,Viktor Szatmári,Pierre Menaut,Whitney M. Church,M.L. O'Sullivan,J. P. Jaudon,Jan-Gerd Kresken,John E. Rush,Kirstie A. Barrett,Steven L. Rosenthal,Ashley B. Saunders,Ingrid Ljungvall,M. Deinert,Eric Bomassi,Amara H. Estrada,M. J. Fernández del Palacio,N.S. Moïse,Jonathan A. Abbott,Yoko Fujii,Alan W. Spier,Michael W. Luethy,Roberto A. Santilli,Masami Uechi,Anna Tidholm,Christoph Matthias Schummer,P. Watson +38 more
TL;DR: Pimobendan treatment reduces heart size and is associated with improved outcome and relationships between short‐term changes in echocardiographic variables and time to CHF or CRD were explored.
Journal ArticleDOI
Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
Adrian Boswood,Sonya G. Gordon,Jens Häggström,Martin Vanselow,Gerhard Wess,Rebecca L. Stepien,Mark A. Oyama,Bruce W. Keene,John D. Bonagura,Kristin A. MacDonald,M. Patteson,Sarah Smith,Philip R. Fox,Karen Sanderson,Richard Woolley,Viktor Szatmári,Pierre Menaut,Whitney M. Church,M. Lynne O'Sullivan,Jean-Philippe Jaudon,Jan-Gerd Kresken,John E. Rush,Kirstie A. Barrett,Steven L. Rosenthal,Ashley B. Saunders,Ingrid Ljungvall,M. Deinert,Eric Bomassi,Amara H. Estrada,María Josefa Fernández del Palacio,N. Sydney Moïse,Jonathan A. Abbott,Yoko Fujii,Alan W. Spier,Michael W. Luethy,Roberto A. Santilli,Masami Uechi,Anna Tidholm,Christoph Matthias Schummer,P. Watson +39 more
TL;DR: Findings reinforce the value of RR and RRR as indicators of impending or incipient CHF.